Search Grants — Free, No Account Required

National Institutes of Health

This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. This NOFO uses a cooperative agreement mechanism (U01) and runs in parallel with a companion NOFO (RFA-DK-27-136).

National Institutes of Health

This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscriptsThe RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design and analysis, 3) providing research coordination with a central laboratory, 4) harmonizing data collection methods and use of common data elements, 5) developing the database; 6) conducting data management and data analyses for Consortium studies; and 7) fostering research collaborations. This NOFO uses a cooperative agreement mechanism (U24) and runs in parallel with a companion NOFO (RFA-DK-27-121).

National Institutes of Health

This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscriptsThe RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design and analysis, 3) providing research coordination with a central laboratory, 4) harmonizing data collection methods and use of common data elements, 5) developing the database; 6) conducting data management and data analyses for Consortium studies; and 7) fostering research collaborations. This NOFO uses a cooperative agreement mechanism (U24) and runs in parallel with a companion NOFO (RFA-DK-27-121).

National Institutes of Health

NIMH seeks applications for pilot research to adapt, optimize, and test behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. This notice of funding opportunity (NOFO) supports pilot clinical trials designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings. Applications should aim to conduct a preliminary test of the intervention's impact on sleep and mental health outcomes, as well as an examination of the mechanisms that underlie the intervention's effectiveness, and to obtain preliminary data needed as a prerequisite for larger-scale effectiveness trials. In addition, interdisciplinary, collaborative teams of investigators from the fields of mental health, sleep medicine, developmental science, clinical trials research methods, behavioral economics, implementation science, data science, and human computer interaction are encouraged.

National Institutes of Health

NIMH seeks applications for pilot research to adapt, optimize, and test behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. This notice of funding opportunity (NOFO) supports pilot clinical trials designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings. Applications should aim to conduct a preliminary test of the intervention's impact on sleep and mental health outcomes, as well as an examination of the mechanisms that underlie the intervention's effectiveness, and to obtain preliminary data needed as a prerequisite for larger-scale effectiveness trials. In addition, interdisciplinary, collaborative teams of investigators from the fields of mental health, sleep medicine, developmental science, clinical trials research methods, behavioral economics, implementation science, data science, and human computer interaction are encouraged.

NIMH - National Institute of Mental Health

PROJECT SUMMARY/ABSTRACT Across sub-Saharan Africa, approximately one-third of new HIV infections occur among men. Men in highly mobile occupations, such as fishing, are particularly vulnerable to poor HIV prevention engagement. Fisherfolk (men and women who work in the fishing industry) are the largest key/priority population in Kenya. Despite significant declines in HIV incidence in other populations in sub-Saharan Africa, fishermen have persistently high rates of HIV acquisition. Kenya has been a leader in scaling up biomedical HIV prevention, including oral tenofovir-based pre-exposure prophylaxis (PrEP), a daily pill that is highly effective with sufficient adherence. However, efforts to improve daily oral PrEP use have not been effectively deployed to address the unique barriers experienced by mobile fishermen, particularly as new HIV prevention technologies and regimens are introduced such as long-acting injectable PrEP (e.g., CAB-LA; injection every 2 months and lenacapavir; injection every 6 months), event- driven PrEP (oral PrEP taken before and after sexual contact), and post-exposure prophylaxis (oral PrEP taken after potential HIV exposure). Without tailored delivery strategies, these innovations risk reproducing the same access and adherence challenges that have limited the impact of existing prevention tools in this population. Evidence-based approaches tailored to the needs of mobile fishermen are urgently needed to optimize their engagement in biomedical HIV prevention. Evidence-based approaches such as differentiated and patient- centered service delivery for HIV prevention have been endorsed by the WHO, yet these service delivery models have not yet been effectively harnessed to improve mobile fishermen’s uptake and adherence to biomedical HIV prevention. Meaningful engagement of community members in tailoring evidence-based HIV interventions is recognized as an approach that may increase sustainability, ownership, and acceptance of interventions. However, established methods to effectively engage mobile populations, including fishermen, in research are limited. Community-led, participatory approaches in global HIV research have infrequently been utilized with priority populations such as mobile fishermen yet may be vital to addressing prevention gaps. The proposed research uses community-engaged and participatory approaches to identify factors influencing fishermen’s engagement in HIV prevention (Aim 1) and to co-design an evidence-based intervention in collaboration with fishermen (Aim 2). The co-designed intervention will then be piloted to evaluate its implementation and client outcomes (Aim 3). Completion of the proposed training and research plan will provide me with an expanded skillset in community-engaged research, intervention design, and implementation science approaches. I will be mentored by a team of experienced Kenyan and UCSF mentors. A future R01 will evaluate the co-designed intervention at scale.

NIMH - National Institute of Mental Health

PROJECT ABSTRACT Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) represent a promising but underutilized class of HIV medications that can significantly benefit patients who struggle with oral medication adherence. Despite their potential, LAIs face substantial implementation barriers due to their logistical complexity compared to traditional oral medications. While high-volume LAI delivery is currently rare across U.S. HIV clinics, clinical decision support (CDS) systems offer a potential solution for efficiently scaling LAI programs. This project addresses the critical need for infrastructural support in LAI delivery by developing and evaluating a comprehensive Resource Package to accelerate the adoption of LAI-specific CDS in HIV clinics nationwide. We hypothesize that providing clinics with a standardized Resource Package will lead to more efficient workflows, improved care coordination, enhanced patient outcomes, and sustainable LAI program growth. The Resource Package will include: (1) a compendium of LAI-specific CDS tool options with implementation guidance, (2) decision-making worksheets for CDS design, (3) low-fidelity prototypes with adaptable wireframes, (4) build checklists for tool development, and (5) evaluation metrics for assessing CDS tools. Our project has three specific aims. First, we will identify promising CDS tools and processes through synthesis of practices at 10 Clinical Partner Sites currently delivering LAIs at high volume. Second, we will co-create the Resource Package through five multi-disciplinary working groups, each including clinicians, CDS end-users, builders, and implementation scientists. Third, we will assess the Resource Package's impact on clinics' readiness to build LAI CDS tools and their progress in the build process through pre-post surveys and in-depth qualitative analysis. The project will be carried out by an interdisciplinary team including implementation scientists, clinicians, and CDS specialists, working collaboratively with 10 Clinical Partner Sites, two national dissemination partners, and a Community Advisory Board. This research directly responds to NIMH priorities (PAR-22-060 and NOT-MH-23-275) by developing a systematic intervention to promote organizational readiness and capacity for implementing LAIs with fidelity and effectiveness. By establishing a standardized approach to CDS development for LAIs, this project aims to overcome a significant barrier to widespread LAI implementation, ultimately expanding access to these valuable HIV prevention and treatment options for vulnerable populations currently underserved by conventional oral medication approaches.

National Institutes of Health

Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Dental and Craniofacial Research and the National Institute on Aging, National Institutes of Health, solicits grant applications from institutions/organizations that propose investigator-initiated clinical research focused on the oral health of special needs populations, including those with developmental or acquired physical or mental disabilities, people with mental retardation (MR), people living with HIV/AIDS, and frail or functionally dependent elders. Mechanism of Support. This FOA will utilize the Research Project Grant (R01) award mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Other(s): Eligible agencies of the Federal government; Faith-based or community based organizations.

NIMH - National Institute of Mental Health

Project Summary/Abstract Depressive symptoms represent a serious challenge to youth mental health. There is therefore an urgent need for the identification of possible mechanisms underlying risk for youth depressive symptoms. This is especially crucial for certain high-risk populations, such as youth with a history of adversity exposure. Dysregulation of the oral microbiome, the community of microorganisms inhabiting the human oral cavity, may function as a mechanism underlying risk for depressive symptoms in youth. The oral microbiome is a compelling putative mechanism for youth depressive symptoms because it is manipulable via non-invasive interventions, such as probiotic supplementation, while, at the same time, remarkably resilient to insults once it has stabilized in early adulthood. Indeed, oral microbiome dysregulation has been linked to depressive symptoms, experimentally in animal models and observationally in human youth. However, in order for potential mechanisms underlying this link to be elucidated, there is a need for research that examines the oral microbiome and depressive symptoms longitudinally, that examines the microbiome at a functional level, and that incorporates neuroimaging to better understand depressive symptom etiology. The current project will address these gaps by leveraging a 3-year longitudinal study of youth, ages 6-16 at the first timepoint (N=152), with the first 2 timepoints completed and the 3rd underway. This project oversamples for adversity-exposed youth (N=66), a population at increased risk of both depressive symptoms and oral microbiome dysregulation. Oral microbiome composition and depressive symptoms will have been assessed at all three timepoints, and functional Magnetic Resonance Imaging (fMRI) conducted at the final timepoint. We will analyze the relationship between the oral microbiome and depressive symptoms, and the relationship between the oral microbiome and functional brain connectivity. We hypothesize that elevated pathogenic taxa, increased pro-inflammatory functions of the oral microbiome, and decreased aromatic amino acid precursor biosynthesis will be associated with increased depressive symptoms. We further hypothesize these same indicators of oral microbiome dysregulation will also be associated with altered functional brain connectivity, especially within the affective limbic network, reward network, default mode network, and cognitive control network. This project’s findings will yield critical understanding about potential peripheral mechanisms underlying depressive symptoms in both typically developing and high-risk youth.

NIMH - National Institute of Mental Health

PROJECT SUMMARY G protein coupled receptor (GPCR) signaling pathways mediate actions of hormones and neurotransmitters. They are essential for the normal function of the nervous system, frequently disrupted in many neuropsychiatric and neurological conditions and/or exploited for therapeutic purposes. While we learned considerable information about molecular players involved in traditional GPCR signaling, many critical gaps remain. Among the biggest uncharted territories in the field is an issue of “orphan” GPCRs, receptors with unknown signaling mechanisms. It is generally recognized that orphan receptors have tremendous potential for uncovering novel biology of the nervous system and harnessing it for potential therapeutic benefits. Our long- term goal is to understand principles in organization and functional regulation of poorly explored GPCR pathways in the effort to develop better treatments for brain disorders. The focus of our attention is on the poorly understood orphan receptor- GPR158, that plays a pivotal role in stress-induced depression. During the previous award period we demonstrated that GPR158 serves as a receptor for major neurotransmitter glycine impacting synaptic transmission and neuronal excitability. We further delineated GPR158 signaling mechanism showing that it associates with a negative regulator of G protein signaling, RGS7 as well as extracellular synaptic proteins and controls production of the second messenger cAMP. We further solved a structure of GPR158 in complex with RGS7 revealing its organization at atomic level. These data led to an overarching hypothesis that glycine signals via GPR158 regulate activity of the associated RGS7 complex which in turn gates cAMP production to regulate neuronal activity that drives stress- induced behavioral changes. This hypothesis will be tested by pursuing three complementary Specific Aims that seek to: (1) establish molecular mechanisms of glycine action on GPR158, (2) delineate structural basis of glycine effects on GPR158 and interaction with binding partners and (3) dissect mechanics of GPR158 signal transduction in regulation of cAMP. The strategy proposed to address these Aims will entail a synergistic combination of biochemical, structural, and cell-biological approaches, exploiting the existence of a powerful array of technologies and animal models. We hope that accomplishment of these goals will provide critical new insights into the mood regulation in mammals and suggest novel targets for the development of therapeutic interventions.

Office for Victims of Crime

This is a notice of funding opportunity (NOFO) for the OVC FY 2026 National Mass Violence Center. This opportunity supports the continued operation of the National Mass Violence Center (NMVC) in preparing for and responding to mass violence incidents; providing services, training, and education; and developing best practices, tools, and strategies to support mass violence victims. The NMVC supports communities experiencing mass violence, including in-person and virtual support for law enforcement and other first responders, survivors, and families. These include assistance implementing victim services (including mental health care and other emergency supports); creating recovery centers; and helping jurisdictions prepare to respond to victims of these incidents. Planning allows stakeholders (e.g., first responders, emergency managers, health professionals, victim services providers, government representatives, faith leaders) to build on and enhance existing emergency response plans to ensure the needs of victims, families, and first responders are addressed after these incidents. NMVC activities emphasize behavioral health including mental health and resiliency in response to mass violence incidents and the integration of victims needs into existing emergency response plans.

Office for Victims of Crime

This is a notice of funding opportunity (NOFO) for the OVC FY 2026 National Mass Violence Center. This opportunity supports the continued operation of the National Mass Violence Center (NMVC) in preparing for and responding to mass violence incidents; providing services, training, and education; and developing best practices, tools, and strategies to support mass violence victims. The NMVC supports communities experiencing mass violence, including in-person and virtual support for law enforcement and other first responders, survivors, and families. These include assistance implementing victim services (including mental health care and other emergency supports); creating recovery centers; and helping jurisdictions prepare to respond to victims of these incidents. Planning allows stakeholders (e.g., first responders, emergency managers, health professionals, victim services providers, government representatives, faith leaders) to build on and enhance existing emergency response plans to ensure the needs of victims, families, and first responders are addressed after these incidents. NMVC activities emphasize behavioral health—including mental health—and resiliency in response to mass violence incidents and the integration of victims’ needs into existing emergency response plans.

NIMH - National Institute of Mental Health

Project Summary Parvalbumin interneurons (PVIs) are essential for regulating cortical network activity, playing key roles in both the primary visual cortex (V1) and in the prefrontal cortex (PFC). PVIs have been implicated in schizophrenia, bipolar disorder, autism, and major depression, with transcriptomic alterations more pronounced than in other neuron types. However, the relationship between these changes in PVIs and corresponding physiological or morphological alterations remains unclear. Assessing these relations is the primary goal of this application. This exploratory R21 proposal investigates, using patch-seq, the properties of PVI subtypes and the effects of social isolation (SI), which induces PVI transcriptome changes in a manner relevant to psychiatric disorders. We will test whether region-specific PVI properties in mouse PFC and V1 contribute to the changes produced by SI. Our pilot studies revealed distinct electrophysiological subtypes of PVIs (continuous firing [cFS] and delayed fast-spiking [dFS]), in PFC and V1, as well as differences in axonal morphology. These baseline differences may contribute to region-specific PVI vulnerability to psychiatric disease or related manipulations. Aim 1 will establish the baseline transcriptomic signatures of PVI subtypes in PFC and V1 under standard group-housed conditions. Using patch-seq, we will integrate single-cell RNA sequencing, electrophysiology, and morphology to define the transcriptional markers distinguishing cFS and dFS subtypes in each region. Aim 2 will determine how SI alters PVI subtypes in PFC and V1 using patch-seq to assess changes in gene expression, excitability, and morphology. By correlating transcriptional changes with cellular phenotypes in the same neurons, this aim will reveal whether region-specific PVI properties shape differential responses to SI. This study is innovative in applying patch-seq to link transcriptional changes to multimodal cellular phenotypes in PVIs. It represents the first investigation of how experimental manipulations affect PVI subtypes across cortical regions. Our findings will provide crucial insights into region-specific PVI dysfunction and generate testable hypotheses on how molecular alterations contribute to disease-relevant cortical circuit changes.

National Institutes of Health

-Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications for research on the pathophysiological aspects of late-life mood and anxiety disorders and on the utility of findings in this research area for developing new treatments or predicting older adults response to existing mental health treatments, and to attract new investigators into interdisciplinary studies of these issues. -Mechanism of Support. This FOA will use the NIH Research Project Grant (R01), but applications under the NIH Small Research Grant Program (R03); the NIH Exploratory/Developmental Research Grant Program (R21); and the NIMH Clinical Exploratory Grant Program (R34) are also sought. Applicants for the R03 should respond to PA-06-180, applicants for the R21 should respond to PA-06-181, and applicants for the NIMH R34 should respond to PA-06-248. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

FDA - Food and Drug Administration

Effective engagement with the public is essential to expand the impact of the U.S. Food and Drug Administration, and for the efficient transfer of information and insights among the Agency, patients, academia, consumers, healthcare, and regulated industry. Through PRISM: Pathways for Regulatory Innovation and Strategic Modernization, the Reagan-Udall Foundation for the FDA proposes a multi-year effort to support the FDA's mission to protect and promote the public's health. As a Congressionally chartered, independent nonprofit, the Foundation serves as a neutral bridge between FDA and diverse stakeholders, delivering applied regulatory science, real-world insights, and transparent engagement. The Foundation does not participate in regulatory decision-making. Building on more than 70 collaborative projects completed between 2020 and 2025, the PRISM project portfolio advances FDA priorities through three Specific Aims: 1) Support the Development and Use of Regulatory Science Tools, 2) Support Programs and Research to Enhance Development of and Access to FDA-Regulated Products, and 3) Engagements, Convenings, and Operational Evaluations to Support the Work of FDA. Aim 1 strengthens regulatory science tools, with emphasis on modern use of real-world data and artificial intelligence, evaluation of data transparency, trust, and governance, and assessment of the predictive utility of animal studies to support efforts to reduce animal testing. Aim 2 focuses on improving development of and access to FDA-regulated products by expanding patient- and consumer-centered initiatives, enabling access to investigational new drugs, studying appropriate use of controlled substances, supporting gold-standard food and nutrition research, incentivizing drug development for animals, and assisting rapid response collaboration during cross-sectoral outbreaks. Aim 3 leverages the Foundation's expertise in convenings—roundtables, expert panels, and public meetings—to support FDA implementation across complex policy areas, including drug development, cosmetics oversight, rare diseases, food safety, mental health, and counterfeit products. Projects are jointly designed with FDA staff, delivered on defined timelines and budgets, and culminate in public outputs to promote learning, transparency, trust, and impact. Collectively, through PRISM, the Foundation provides FDA with timely evidence, stakeholder insight, and practical tools to modernize regulatory science and address emerging public health challenges efficiently, transparently, and in a trustworthy manner.

NIMH - National Institute of Mental Health

PROJECT SUMMARY/ABSTRACT Suicide is the second leading cause of death among young adults ages 15-241, with rates continuing to rise2. While research has identified some broad predictive factors3, our ability to predict who will experience suicidal thoughts and behaviors (STB) and when these crises will occur remains limited4. This challenge stems from the fact that suicide risk fluctuates dramatically in response to emotional and interpersonal distress5,6, with social threats often acting as precipitating events7,8. The tendency to respond impulsively to negative emotions (e.g., negative urgency9) may help explain why some individuals engage in STB as a maladaptive attempt to escape emotional pain following social threat or rejection. Evidence from neuroscience indicates that social- affective circuitry reflects subjective affective sensitivity to social threat10,11, and overlaps with putative neural correlates of negative urgency12,13, suggesting a potential neural profile that may drive associations between social threat and STB. To test this, I will utilize data from an ongoing R01 including 6 months of ecological momentary assessment (EMA), a personalized peer social feedback fMRI task, and self-report questionnaires from 150 young adults (ages 18-30) with chronic STB to examine how function in social-affective systems and real-world experiences of social threat interact to predict STB. The Specific Aims of this study are to: (1) test associations between negative urgency and STB using both baseline and prospective EMA assessments; (2) investigate associations between functional connectivity of social-affective systems during social threat and trait-level negative urgency; and (3) examine whether individual differences in neural response to social threat moderate same-day relationships between social rejection-generated negative affect and suicidal thoughts. This project, and the associated F31 fellowship at the University of Pittsburgh, will provide critical training for the applicant to become an independent researcher investigating how neural and behavioral responses to social contexts influence suicide risk during key developmental periods. To accomplish the proposed research, this application includes a comprehensive training and mentorship plan that builds on the applicant’s prior clinical psychology and developmental neuroscience training. These Training Goals will focus on expanding the applicant’s knowledge and/or skills in: (1) neurodevelopmental pathways to suicide; (2) negative urgency as a mechanism of suicidal thoughts; (3) task-based fMRI methods, with an emphasis on functional connectivity analyses; and (4) implementing mixed-effects modeling for intensive longitudinal data. These goals will be accomplished through mentorship meetings, workshops, conferences, and coursework with a committed interdisciplinary team. Complemented by support from a dedicated research environment at the University of Pittsburgh, this fellowship will accelerate the applicant’s trajectory toward becoming an independent researcher focused on using multimodal research to identify how individual neurobiology interacts with one’s social environment to create enduring risk for STB.

U.S. Mission to Poland

Purpose of Grants: PD Poland invites proposals for programs that strengthen ties between the United States and Poland through activities that highlight shared values, promote bilateral cooperation, and forge enduring connections between the United States and emerging Polish leaders (high school students, university students, and young professionals ages 16 to 35), as well as established community leaders in the public, private, and nonprofit sectors. All proposals are required to have a clear connection to the United States, either through U.S. organizations, experts, and/or best practices in order to increase the awareness and understanding of U.S. perspectives, policies, and society. Proposals without significant U.S. content will not be considered for funding. Examples of possible public diplomacy grant activities include, but are not limited to: Youth engagement programs. Participatory and/or problem-solving workshops like tech camps. Soft skills and leadership-building workshops, seminars, and trainings that develop human capital and social or economic innovation. Workshops, seminars, trainings, master classes, and exhibitions on themes or topics that advance shared democracy, economic, and security goals. Programs that reinforce and amplify lessons learned by Polish alumni of U.S. Government-funded and private sector exchange programs. Priority Program Areas: ECONOMIC PROSPERITY Addressing barriers to the advancement of women in STEM fields and business. Strengthening the business skills of young entrepreneurs. Sharing best practices of U.S. businesses operating in Poland. Promoting the development of trade and investment with the United States, including entrepreneurship, small- and medium-sized businesses, and innovation as the basis for strong, sustainable, inclusive economic growth that creates quality employment and incorporates diverse and excluded groups. Promoting joint Polish-U.S. science, space, and innovation initiatives carried out by research organizations, nongovernmental organizations, universities, and private companies. ENSURING SECURITY Demonstrating the benefits of the of the Polish-U.S. security partnership and NATO Alliance for Polish emerging leaders (high school and university students ages 15-25 and/or young professionals ages 25-34). Promoting a deeper understanding of the impact of Polish and U.S. political, military, and humanitarian support for Ukraine and for Ukrainians in Poland. Strengthen cyber security awareness. STRENGTHENING DEMOCRACY Leadership training fostering innovation and critical thinking among young people (ages 16 to 24). Strengthening media practitioners and media consumers media literacy and ability to detect and combat mis/disinformation. Promoting Holocaust education and/or human rights education. Participants and Audiences: Proposals should describe both the primary and secondary audiences for the program, including anticipated numbers to be reached. Primary audiences are those who will participate directly in the program, while secondary audiences are those who will be reached by the project s primary audiences as a result of their participation. Priority target audiences in Poland for this funding opportunity are youth and young professionals (aged 16 to 35) who have demonstrated strong leadership potential, established professionals engaged in fields relevant to the U.S.-Polish partnership, and community leaders. The following types of programs are not eligible for funding: Programs relating to partisan political activity; Charitable, clinical (including mental health services), or development activities; Construction programs; Programs that support specific religious activities; Fund-raising campaigns; Lobbying for specific legislation or programs; Academic or scientific research; Programs intended primarily for the growth or institutional development of the organization; and Individual travel to attend a conference and/or courses at any educational institution. This funding opportunity aims to support specific projects with objectives that can be achieved within a set timeframe. We will not accept applications that are aimed more broadly at supporting your organization s usual or typical daily activities and operations. Those will be deemed technically ineligible and will not be considered for funding by the review committee.

NIMH - National Institute of Mental Health

PROJECT SUMMARY The proposed fellowship aims to prepare the applicant, Ananya Bhaktaram, for a career as a leading mixed methods researcher who examines the influence of social and spatial factors on social relationships and health. To develop the skillset necessary to become a leading expert, Ms. Bhaktaram proposes to investigate social and spatial factors that influence social connectedness and mental health, substance use, and HIV- related behaviors and outcomes in people living with HIV (PLWH) and populations highly affected by HIV (PHAH). Ms. Bhaktaram will conduct the proposed research while engaging in individualized mentorship, by a team of complementary experts to target the following training objectives: 1) Build competence in qualitative methodologies, and mixed methods approaches; 2) Enhance expertise in theory-driven geospatial analysis; 3) Advance expertise in advanced quantitative methods; 4) Cultivate a strong foundation in research ethics; 5) Engage in professional development opportunities to ensure success as an independent researcher. The proposed research is highly relevant for addressing mental health, substance use, and HIV comorbidities among PLWH/PHAH. Loneliness and social isolation have comparable levels of risk to health and premature death as smoking and obesity. Social connectedness is an important comorbid risk factor for poor/worse HIV- related outcomes, as social connections can serve as protective factors by acting as sources of resource and instrumental support. PLWH/PHAH report higher levels of loneliness and social isolation. Gaining insight into the social and spatial factors that influence social connectedness will allow for better assessment of future intervention points to improve mental health, substance use, and HIV-related comorbidities. To address these gaps, the proposed research will use data collected by Dr. Carl Latkin’s (Sponsor) research team at the Lighthouse to 1) Assess associations between social connection, mental health, substance use, and HIV-related behaviors and outcomes in PLWH/PHAH; 2) Explore social and spatial dynamics that characterize, facilitate, and hinder social connectedness among PLWH/PHAH; 3) Examine the relationship between spatial factors, social connectedness, HIV, and mental health related outcomes. Findings from this study will provide insight into the social and geographic factors that influence loneliness and social isolation to inform measurement and targeted strategies for preventive interventions, while offering conceptual insight that can improve the understanding of the distinct pathways of loneliness and social isolation. The proposed research aligns with Goals 2 and 3 of the NIMH’s Strategic Plan by providing conceptual and contextual evidence to understand mental illness trajectories and enhance prevention strategies to improve mental health, substance use, and HIV comorbidities in PLWH/PHAH.

NYS Office of Mental Health

6340 ? Comprehensive PROS with Clinic Personalized Recovery Oriented Services (PROS) is a comprehensive recovery oriented program for individuals with severe and persistent mental illness. The goal of the program is to integrate treatment, support and rehabilitation in a manner that facilitates the individual's recovery. Goals for individuals in the program are to: improve functioning, reduce inpatient utilization, reduce emergency services, reduce contact with the criminal justice system, increase employment, attain higher levels of education and secure preferred housing. There are four "service components" in the program: Community Rehabilitation and Support, Intensive Rehabilitation, Ongoing Rehabilitation and Support and Clinical Treatment. Units of Service: Report the sum of the total monthly units of service for the year 7340 ? Comprehensive PROS without Clinic PROS is a comprehensive recovery oriented program for individuals with severe and persistent mental illness. The goal of the program is to integrate treatment, support and rehabilitation in a manner that facilitates the individual's recovery. Goals for individuals in the program are to: improve functioning, reduce inpatient utilization, reduce emergency services, reduce contact with the criminal justice system, increase employment, attain higher levels of education and secure preferred housing. There are four "service components" in the program: Community Rehabilitation and Support, Intensive Rehabilitation, Ongoing Rehabilitation and Support and Clinical Treatment. This program does not include the optional Clinic Treatment component. Units of Service: Report the sum of the total monthly units of service for the year

NIMH - National Institute of Mental Health

PROJECT SUMMARY / ABSTRACT Despite availability of HIV pre-exposure prophylaxis (PrEP) for over a decade, many persons who could benefit from PrEP have not yet accessed PrEP services. Implementation of pharmacy-based PrEP is a promising strategy that presents opportunity to overcome barriers related to clinic distance and stigma and to increase PrEP access, uptake, and continuity of treatment among individuals who would benefit most. Despite the fact that team member and pharmacist Dr. Elyse Tung started the first pharmacy-based PrEP clinic nearly ten years ago, PrEP still is not widely available through pharmacies without a prescription from a doctor or other licensed clinician. As of 2024, not all states allow pharmacists to prescribe medications independently, and many insurance companies erect barriers to providing compensation to pharmacists for this role. Implementation science projects are needed to develop, refine, and evaluate the training and educational support required by pharmacists to expand their scope of practice. Health economics work is also needed to determine whether there are incremental financial benefits for pharmacies to provide injectable PrEP in addition to oral medications and to evaluate the cost-effectiveness of providing PrEP through telehealth. In response to RFA MH-25-185, we propose three specific aims. Aim 1 will build on a current supplement through the Ending the HIV Epidemic (EHE) initiative that is funding a pilot project to evaluate an online virtual community of practice (VCoP) for pharmacists and pharmacy staff to increase their knowledge, capabilities, and comfort in prescribing PrEP. Aims 2 and 3 will conduct financial analyses to provide information for new pharmacy implementation and use time and motion data to compare the costs and benefits of providing injectable PrEP versus oral PrEP and in-pharmacy visits versus telePrEP. This project addresses the Prevent pillar of the EHE plan with a secondary impact on the Diagnose pillar. This project also addresses the NIH HIV/AIDS Research Priorities (NOT-OD-20-018) to reduce HIV incidence by testing new prevention strategies and training the workforce. It is in synergy with the local EHE plan, the Washington State Department of Health, and the National HIV/AIDS Strategy. The national strategy specifically calls out to leverage pharmacists’ knowledge and accessibility in nearly every urban and rural community as part of a comprehensive HIV prevention and care strategy. Ultimately our goal is to provide more PrEP options and motivate pharmacists and pharmacy owners to expand access points for PrEP care in locations and to populations disproportionately impacted by HIV infection in order to end the HIV epidemic.

NIDA - National Institute on Drug Abuse

PROJECT SUMMARY Substance use disorders are a major cause of death and disease in the United States with the country currently experiencing over 100,000 drug overdose deaths 1 and over 5 million disability adjusted life years (DALY’s: equal to one year of healthy life lost) per year. While overall, overdose deaths are declining, this is not the case in all demographics and communities, suggesting that as we address challenges related to substance use disorders (SUDs), many subpopulations are being left behind. These differences highlight the need to consider the unique circumstances of individuals in different subpopulations. Substance misuse and SUD are highly personalized phenomena, influenced by a complex interplay of psychosocial, environmental, genetic, and other unique factors. Psychosocial factors, such as stress, trauma, and social relationships can either predispose individuals to drug use or protect them from it. Environmental influences, including socioeconomic status and injury can also intersect to shape susceptibility to substance misuse and SUD. Additionally, individual differences in brain chemistry, personality traits, and co-occurring mental health disorders contribute to the variability in addiction vulnerability. Thus, there is a need to train the next generation of researchers to understand and study the influences of individualized factors on susceptibility and treatment responses in substance misuse. We are requesting three predoctoral training slots for a duration of five years (two supported by this award, one supported by the Medical College of Wisconsin Graduate School). The Pharmacology Research on Individualized factors in Substance Misuse (PRISM) Training Program is designed to meet this need by providing trainees with in-depth experiences and a holistic education on the impact of unique factors on addiction liability. In the lab, PRISM scholars will study the influence of personalized factors on substance misuse in one of several themes, including stress, neuroinflammation, circuits/plasticity, chronic pain, brain injury, and/or endocannabinoid signaling. Outside the lab, PRISM scholars will get real-world experiences to begin to understand the bidirectional impact of substance use disorders on individuals and communities. These experiences include shadowing practitioners and harm reduction specialists, learning from people with lived experience, and engaging community partners in Milwaukee to discuss scientific and community aspects of substance misuse. To further promote professional development and a broad exposure to different applications of substance misuse research, PRISM scholars will complete a capstone project in one of five themes: community engagement, policy, industry, teaching/education, or translational research. Completion of the capstone project will be supported by a specific capstone mentor and participation in PRISM scholars Learning Community events. By integrating these comprehensive training components, the PRISM Training Program aims to cultivate a new generation of researchers equipped to address the individual challenges of substance misuse.

National Institutes of Health

The National Institute on Drug Abuse seeks to support pilot and feasibility studies in preparation for efficacy, effectiveness and/or services research trials. Topics may include:1) developing interventions to prevent substance use, misuse or progression to disorder, 2) substance use prevention, treatment or recovery services research, including comorbid pain, medical and mental health disorders, 3) HIV eradication research, including implementation science, prevention, treatment and recovery in substance use settings/populations.Projects may address information gaps, strengthen stakeholder partnerships, or pilot test interventions. Activities might include intervention development/adaptation; assessing intervention or service model acceptability and feasibility; and development of measures, materials, or methods for the future trial. Preliminary data is not required. A well-defined theory of change or logic model is expected. Applicants must engage relevant end users in study design, execution, and interpretation (e.g., policymakers, state and local decision makers, practitioners, individuals with lived/living experience, families, youth, and community members).Applications are not being solicited at this time. This notice is to allow applicants time to develop collaborations and responsive projects. Grant authorities that allow this forecast are 42 U.S.C. 241 and 284.

National Institutes of Health

<p>The National Institute on Drug Abuse seeks to support pilot and feasibility studies in preparation for efficacy, effectiveness and/or services research trials. Topics may include:1) developing interventions to prevent substance use, misuse or progression to disorder, 2) substance use prevention, treatment or recovery services research, including comorbid pain, medical and mental health disorders, 3) HIV eradication research, including implementation science, prevention, treatment and recovery in substance use settings/populations.</p><p>Projects may address information gaps, strengthen stakeholder partnerships, or pilot test interventions. Activities might include intervention development/adaptation; assessing intervention or service model acceptability and feasibility; and development of measures, materials, or methods for the future trial. Preliminary data is not required. A well-defined theory of change or logic model is expected. Applicants must engage relevant end users in study design, execution, and interpretation (e.g., policymakers, state and local decision makers, practitioners, individuals with lived/living experience, families, youth, and community members).</p><p>Applications are not being solicited at this time. This notice is to allow applicants time to develop collaborations and responsive projects. Grant authorities that allow this forecast are 42 U.S.C. §§ 241 and 284.</p><p>&nbsp;</p>

National Institutes of Health

NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This Notice of Funding Opportunity (NOFO) supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01 currently TEMP-24813.